Description
PRINROOT-4
Perindopril Erbumine 4 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Perindopril Erbumine IP — 4 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
PRINROOT-4 contains Perindopril Erbumine 4 mg, a long-acting angiotensin-converting enzyme (ACE) inhibitor formulated for the effective management of hypertension, heart failure, stable coronary artery disease, and long-term cardiovascular risk reduction. Perindopril provides sustained blood pressure control by inhibiting the renin-angiotensin-aldosterone system (RAAS), promoting vasodilation, reducing cardiac workload, and protecting cardiovascular and renal function.
Perindopril Erbumine is widely prescribed in cardiology, nephrology, and internal medicine for patients with essential hypertension, diabetes-associated hypertension, chronic kidney disease, left ventricular dysfunction, and established cardiovascular disease. It helps reduce blood pressure, improve endothelial function, decrease arterial stiffness, and lower the risk of myocardial infarction, stroke, heart failure progression, and cardiovascular mortality.
PRINROOT-4 is particularly beneficial for patients requiring effective blood pressure control along with cardiovascular and renal protection, making it an important therapy in preventive cardiology and diabetic vascular care.
Technical Knowledge of Perindopril Erbumine
Perindopril is converted in the liver to its active metabolite Perindoprilat, which inhibits angiotensin-converting enzyme. This reduces the formation of angiotensin II, decreases aldosterone secretion, promotes vasodilation, reduces sodium and water retention, improves endothelial function, and enhances arterial compliance.
Perindopril also reduces bradykinin degradation, contributing to improved vascular function and nitric oxide-mediated vasodilation. Its long duration of action provides effective once-daily blood pressure control and sustained cardiovascular protection.
Mechanism of Action
Perindopril inhibits angiotensin-converting enzyme, reduces angiotensin II formation, decreases aldosterone secretion, promotes vasodilation, improves endothelial function, reduces peripheral vascular resistance, decreases cardiac afterload, and provides cardiovascular and renal protection.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Provides sustained 24-hour blood pressure control
Supports cardiovascular and renal protection
Improves endothelial function
Reduces arterial stiffness
Decreases cardiac workload
Helps prevent cardiovascular events
Suitable for long-term hypertension and cardiovascular management under medical supervision
Clinical Applications
PRINROOT-4 is commonly prescribed for essential hypertension, hypertension with diabetes mellitus, hypertension with chronic kidney disease, heart failure, stable coronary artery disease, left ventricular dysfunction, cardiovascular risk reduction, and long-term antihypertensive management.
Facts About Perindopril Erbumine
Perindopril is an evidence-based ACE inhibitor with extensive clinical research demonstrating significant reductions in cardiovascular morbidity and mortality. It is widely recommended in international hypertension, heart failure, and coronary artery disease guidelines because of its proven benefits in blood pressure control, vascular protection, and prevention of major cardiovascular events.
Key Facts
Long-acting ACE inhibitor
Perindopril Erbumine 4 mg for cardiovascular and renal protection
Provides sustained 24-hour antihypertensive action
Effective in hypertension, heart failure, and coronary artery disease
Supports long-term cardiovascular risk reduction
Evidence-based ACE inhibitor therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
PRINROOT-4 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose PRINROOT-4 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Perindopril Erbumine 4 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
PRINROOT-4 from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based ACE inhibitor therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Perindopril formulation.